SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%
News
ASMB
--
0.00%
--
Assembly Bio's ABI-H2158 Fast Track'd in U.S. for hepatitis B infection
The FDA designates Assembly Biosciences' (NASDAQ:ASMB) Phase 2-stage ABI-H2158, a second-generation core inhibitor, for Fast Track review for the treatment
seekingalpha · 3d ago
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
GlobeNewswire · 3d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 3d ago
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 07/02 21:30
Assembly Bio commences mid-stage study of HBV candidate ABI-H2158
Seeking Alpha - Article · 06/25 13:34
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
GlobeNewswire · 06/25 13:00
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 For Chronic Hepatitis B Infection
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences,
Benzinga · 06/25 12:08
How Assembly Biosciences (ASMB) Stock Stands Out in a Strong Industry
Zacks · 06/24 13:55
Hedge Funds Still Bullish On Assembly Biosciences Inc (ASMB)
Insider Monkey · 06/23 16:42
Regeneron's Latest Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/22 18:54
Preclinical Data from Assembly Biosciences Immuno-Oncology Microbiome Program Featured at AACRs Virtual Annual Meeting II
GlobeNewswire · 06/22 13:45
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
Benzinga · 06/19 12:41
What You Need To Know About The Assembly Biosciences, Inc. (NASDAQ:ASMB) Analyst Downgrade Today
Simply Wall St. · 06/19 11:02
Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs
GlobeNewswire · 06/18 21:01
Assembly Biosciences Regains Worldwide Rights To Microbiome Gastrointestinal Development Programs
SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and
Benzinga · 06/18 20:01
Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/01 21:18
Assembly Biosciences Appoints William Delaney As Chief Scientific Officer
Benzinga · 05/27 12:18
Assembly Biosciences Announces Management Transition
-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology --  -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire --.
GlobeNewswire · 05/27 12:00
Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
GlobeNewswire · 05/26 12:00
Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
This change is to protect the safety, health and well-being of its stockholders, directors, employees and the public during the COVID-19 pandemic. Stockholders will not be able to attend the Annual Meeting in person at a physical location. Despite the change
GlobeNewswire · 05/19 20:05